Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Weight loss correlates with macrophage inhibitory cytokine-1 expression and might influence outcome in patients with advanced esophageal squamous cell carcinoma.

Lu ZH, Yang L, Yu JW, Lu M, Li J, Zhou J, Wang XC, Gong JF, Gao J, Zhang XT, Li J, Li Y, Shen L.

Asian Pac J Cancer Prev. 2014;15(15):6047-52.


Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance?

Lu Z, Yang L, Yu J, Lu M, Zhang X, Li J, Zhou J, Wang X, Gong J, Gao J, Li J, Li Y, Shen L.

PLoS One. 2014 Feb 28;9(2):e88553. doi: 10.1371/journal.pone.0088553. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e97385.


Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.

Wang XB, Jiang XR, Yu XY, Wang L, He S, Feng FY, Guo LP, Jiang W, Lu SH.

Cancer Sci. 2014 Feb;105(2):176-85. doi: 10.1111/cas.12331. Epub 2014 Jan 2.


High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.

Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, Chang DT, Koong AC.

Ann Surg Oncol. 2014 Jul;21(7):2361-8. doi: 10.1245/s10434-014-3611-z. Epub 2014 Mar 13.


Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.

Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A.

Clin Transl Oncol. 2006 Jan;8(1):22-30.


Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.

Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP.

Ann Thorac Surg. 2008 Jun;85(6):1930-6; discussion 1936-7. doi: 10.1016/j.athoracsur.2008.01.097.


Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.

Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M.

J Thorac Cardiovasc Surg. 2008 Jul;136(1):205-12, 212.e1-3. doi: 10.1016/j.jtcvs.2008.02.016. Epub 2008 May 27.


Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis.

Akita H, Doki Y, Yano M, Miyata H, Miyashiro I, Ohigashi H, Ishikawa O, Nishiyama A, Imaoka S.

Dis Esophagus. 2009;22(4):291-7. doi: 10.1111/j.1442-2050.2008.00879.x. Epub 2008 Nov 19.


Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.

Zhang HQ, Wang RB, Yan HJ, Zhao W, Zhu KL, Jiang SM, Hu XG, Yu JM.

Asian Pac J Cancer Prev. 2012;13(1):199-203.


Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma.

Zhang D, Zhou X, Bao W, Chen Y, Cheng L, Qiu G, Sheng L, Ji Y, Du X.

Oncotarget. 2015 Nov 10;6(35):38410-20. doi: 10.18632/oncotarget.4800.


Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.

Song B, Cui H, Li Y, Cheng C, Yang B, Wang F, Kong P, Li H, Zhang L, Jia Z, Bi Y, Wang J, Zhou Y, Liu J, Wang J, Zhao Z, Zhang Y, Hu X, Shi R, Yang J, Liu H, Yan T, Li Y, Xu E, Qian Y, Xi Y, Guo S, Chen Y, Wang J, Li G, Liang J, Jia J, Chen X, Guo J, Wang T, Zhang Y, Li Q, Wang C, Cheng X, Zhan Q, Cui Y.

Oncotarget. 2016 Jan 19;7(3):3599-613. doi: 10.18632/oncotarget.6120.


Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy.

Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH.

Oncology. 2010;79(5-6):363-9. doi: 10.1159/000322498. Epub 2011 Mar 24.


Inflammation-based prognostic system predicts postoperative survival of esophageal carcinoma patients with normal preoperative serum carcinoembryonic antigen and squamous cell carcinoma antigen levels.

Ma Q, Liu W, Jia R, Jiang F, Duan H, Lin P, Zhang L, Long H, Zhao H, Ma G.

World J Surg Oncol. 2016 May 5;14:141. doi: 10.1186/s12957-016-0878-5.


The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.

Jia J, Cui Y, Lu M, Wang X, Li J, Li J, Li Y, Zhang X, Gao J, Zhou J, Lu Z, Gong J, Yu J, Sun Z, Liu C, Shen L, Zhang X.

Clin Transl Oncol. 2016 Jun;18(6):592-8. doi: 10.1007/s12094-015-1406-8. Epub 2015 Oct 12.


The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.

Qin RQ, Wen YS, Wang WP, Xi KX, Yu XY, Zhang LJ.

Med Oncol. 2016 Apr;33(4):31. doi: 10.1007/s12032-016-0746-8. Epub 2016 Feb 27.


Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy.

Chen YF, Li Q, Chen DT, Pan JH, Chen YH, Wen ZS, Zeng WA.

Cancer Biomark. 2016 Jun 7;17(1):89-96. doi: 10.3233/CBM-160621.


CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Sato Y, Motoyama S, Nanjo H, Wakita A, Yoshino K, Sasaki T, Nagaki Y, Liu J, Imai K, Saito H, Minamiya Y.

Ann Surg Oncol. 2016 Mar;23(3):936-42. doi: 10.1245/s10434-015-4909-1. Epub 2015 Oct 13.


Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma.

Tsuchiya Y, Onda M, Sasajima K, Yamashita K, Nomura T, Makino H, Maruyama H, Hagiwara N, Takubo K, Miyashita M.

Dis Esophagus. 2002;15(3):226-31.


Supplemental Content

Support Center